Relay Therapeutics vs Taysha Gene Therapies
RLAY and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RLAY and TSHA compare
Relay Therapeutics is the larger company, worth 2.8 times as much as Taysha Gene Therapies ($3.6B against $1.3B).
Relay Therapeutics grew revenue faster over the last twelve months (23.9% versus −32.3% for Taysha Gene Therapies).
Taysha Gene Therapies keeps more of each dollar of sales as profit, with a net margin of −2728% compared with −2764% at Relay Therapeutics.
Relay Therapeutics scores higher on the StockData Score (10 against 5 for Taysha Gene Therapies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RLAY | TSHA |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | $1.3B |
| Share price | $16.47 | $4.00 |
| Change, 1 year | 162% | −3.1% |
| Change, 5 years | −44.8% | −68.5% |
| Beta (5Y) | 1.96 | 2.80 |
| Employees | 192 | 99 |
| StockData Score | ||
| Total score | 10 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 349× | 238× (better) |
| P/B | 4.1× | 3.4× (better) |
| FCF yield | – | −10.2% |
| Growth | ||
| Revenue growth (TTM) | 23.9% (better) | −32.3% |
| Revenue growth, 5Y average | −28.6% | – |
| Profitability | ||
| Operating margin | −2999% | −2792% (better) |
| Net margin | −2764% | −2728% (better) |
| FCF margin | – | −2417% |
| Return on equity | −36.8% (better) | −47.1% |
| Return on invested capital | −37.1% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.13 (better) |
| Interest coverage | – | −3646.6× |
| Current ratio | 18.27 (better) | 17.76 |
| Altman Z-score | 24.86 (better) | 7.07 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 113% | 91.9% |
| Held by insiders | 24.5% | 10.7% |
| Insider net buying, 12 months | −$129M | −$6.1M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 26.4% | 18.4% |
Go deeper
- RLAY stock overview
- RLAY income statement
- RLAY valuation and score
- TSHA stock overview
- TSHA income statement
- TSHA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.